• Novartis touts Cosentyx over Johnson & Johnson’s Stelara in psoriasis drug fight

    • March 6, 2019
    • Posted By : admin
    • 0 Comment
    •   49 views

    NOVARTIS COSENTYX SHOWS SUPERIOR IMPROVEMENTS IN PSORIASIS PATIENTS’ QUALITY OF LIFE VERSUS JOHNSON & JOHNSON UNIT JANSSEN’S IL-23 STELARA

    * NOVARTIS SAYS COSENTYX SHOWS SUPERIOR IMPROVEMENTS IN PSORIASIS PATIENTS’ QUALITY OF LIFE VERSUS JANSSEN’S IL-23 STELARA

    * IN ADDITION, NEW PROSE STUDY DATA PRESENTED AS A LATE-BREAKER SUPPORTING BENEFIT OF COSENTYX TO IMPROVE PATIENT QOL

    * COSENTYX CONTINUES TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE

    * J&J PREVIOUSLY PUBLISHED STUDY SHOWING STELARA BEAT COSENTYX

  49 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!